Meridian Bioscience, Inc. Launches Para-Pak SVT (Single Vial Transport)

CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced the launch of Para-Pak^® SVT, a one-vial, multi-purpose, transport solution for the collection, transportation, preservation and examination of intestinal parasites in stool specimens. Traditional Ova & Parasite (O&P) examination procedures, as well as fecal antigen immunoassay tests, require different types of preservatives/transports to run a complete parasitological examination. Para-Pak SVT allows laboratorians to perform all of the testing from one vial, a significant improvement over multi-vial systems. Stool specimens preserved in Para-Pak SVT can be used for direct examination, concentration, permanent stain and will not interfere with fecal immunoassays. The new Para-Pak SVT (Single Vial Transport) is also mercury, PVA and formalin free, a more eco-friendly alternative for the laboratories when it comes to handling and disposal.

According to Mike Shaughnessy, Executive Vice President and President of Meridian Global Diagnostics, “Over 20,000,000 stool transport systems are used in the US annually and the development of Para-Pak SVT provides a simplified solution for healthcare providers by offering a one patient–one transport vial approach that helps reduce potential errors associated with traditional multi-vial systems, and also offers improved work-flow options for laboratories. This is a single transport system that is cost effective and adds testing flexibility to the lab, allowing them to perform from O&P’s and fecal immunoassays from one vial.” As experts in parasitology and leaders in pre-analytic collection systems, including stool collection and transport systems, Meridian Bioscience continues to develop innovative products that meet the needs of today’s healthcare providers.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.